The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Trial of solanezumab in preclinical Alzheimer's disease
Open accessAbstract
Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer’s disease have had mixed results. Download a PDF of the Research Summary. We tested solanezumab, which targets monomeric amyloid, in a phase 3 trial involving persons with preclinical Alzheimer’s disease. Persons 65 to 85 years of age with a global Clinical Dementia Rating score of 0 (range, 0 to 3, with 0 indicating no cognitive impairment and 3 severe dementia), a score on the Mini–Mental State Examination of 25 or more (range, 0 to 30, with lower scores indicating poorer cognition), and elevated brain amyloid levels on 18F-florbetapir positron-emission tomography (PET) were enrolled. Participants were randomly assigned in a 1:1 ratio to receive solanezumab at a dose of up to 1600 mg intravenously every 4 weeks or placebo. The primary end point was the change in the Preclinical Alzheimer Cognitive Composite (PACC) score (calculated as the sum of four z scores, with higher scores indicating better cognitive performance) over a period of 240 weeks. A total of 1169 persons underwent randomization: 578 were assigned to the solanezumab group and 591 to the placebo group. The mean age of the participants was 72 years, approximately 60% were women, and 75% had a family history of dementia. At 240 weeks, the mean change in PACC score was −1.43 in the solanezumab group and −1.13 in the placebo group (difference, −0.30; 95% confidence interval, −0.82 to 0.22; P=0.26). Amyloid levels on brain PET increased by a mean of 11.6 centiloids in the solanezumab group and 19.3 centiloids in the placebo group. Amyloid-related imaging abnormalities (ARIA) with edema occurred in less than 1% of the participants in each group. ARIA with microhemorrhage or hemosiderosis occurred in 29.2% of the participants in the solanezumab group and 32.8% of those in the placebo group. Solanezumab, which targets monomeric amyloid in persons with elevated brain amyloid levels, did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer’s disease. (Funded by the National Institute on Aging and others; A4 ClinicalTrials.gov number, NCT02008357.) QUICK TAKE VIDEO SUMMARYSolanezumab in Preclinical Alzheimer’s Disease 02:05
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly a trial of solanezumab did not slow cognitive decline in people with pre-clinical Alzheimer's disease , did not affect amyloid plaque level but influenced CDR-SB in line with the other studies (0.34). (498) (497)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [498]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“approximately 30% of participants in either group progressed to symptomatic AD (stage 3 or stage 4 of AD).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The A4 (Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease) study, a 5-year clinical trial examining the effects of solanezumab in asymptomatic individuals with amyloid accumulation, failed to show significant cognitive benefits.14”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, the participants who eventually progressed, in fact, had higher levels of accumulated Aβ42 levels measured in post-treatment PET.”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“In a more recent phase 3 trial (NCT02008357), solanezumab failed to meet primary and secondary outcomes, as the drug did not slow cognitive decline in preclinical AD or reduce the risk of progression to symptomatic AD [80].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Despite a well-defined study population and an extended treatment period, results indicated no substantial difference in cognitive decline between the treatment and placebo groups.”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“The A4 study was designed to test whether solanezumab could slow cognitive decline by targeting monomeric amyloid in preclinical AD, but the trial showed no significant effect compared to placebo. 4”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“The A4 study was a multicenter, Phase 3, double‐blind, placebo‐controlled study in subjects with preclinical AD. 4”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Wechsler D. WMS-R: Wechsler Memory Scale–Revised: manual. San Antonio, TX: Psychological Corporation, 1987.
- Wechsler D. Wechsler Adult Intelligence Scale–Revised. San Antonio, TX: Psychological Corporation, 1981.
- Genentech. Genentech provides update on phase III GRADUATE program evaluating gantenerumab in early Alzheimer’s disease. November 13 2022 (https://www.gene.com/media/press-releases/14974/2022-11-13/genentech-provides-update-on-phase-iii-g).
Cited by
Sorted by citations
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Safiri, S., Jolfayi, A. G., Fazlollahi, A., Morsali, S., Sarkesh, A., Sorkhabi, A. D., Golabi, B., Aletaha, R., Asghari, K. M., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 273
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Therriault, J., Schindler, S. E., Salvadó, G., Pascoal, T. A., Benedet, A. L., Ashton, N. J., Karikari, T. K., Apostolova, L. G., Murray, M. E., Verberk, I. M. W., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00942-2 · Cited by 225
Self-citationAccelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197
Self-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 163
Self-citationSperling, R. A., Donohue, M., Rissman, R. A., Johnson, K. A., Rentz, D. M., Grill, J. D., Heidebrink, J. L., Jenkins, C., Jimenez‐Maggiora, G. A., Langford, O., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.122 · Cited by 124
Self-citationAlzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 107
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box
Young, A. L., Oxtoby, N. P., Garbarino, S., Fox, N. C., Barkhof, F., Schott, J. M., & Alexander, D. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00779-6 · Cited by 120
Ossenkoppele, R., Salvadó, G., Janelidze, S., Binette, A. P., Bali, D., Karlsson, L., Palmqvist, S., Mattsson, N., Stomrud, E., Therriault, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00835-z · Cited by 144
Self-citationEbell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Self-citationTreatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“In a more recent phase 3 trial (NCT02008357), solanezumab failed to meet primary and secondary outcomes, as the drug did not slow cognitive decline in preclinical AD or reduce the risk of progression to symptomatic AD [80].”
BackgroundAlzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms
Greenberg, S. M., Bax, F., & van Veluw, S. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-024-01053-8 · Cited by 107
Avgerinos, K. I., Manolopoulos, A., Ferrucci, L., & Kapogiannis, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-75204-8 · Cited by 84
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 87
Self-citationA 2025 update on treatment strategies for the Alzheimer’s disease spectrum
Wu, C.-K., & Fuh, J.-L. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001252 · Cited by 77
Granzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
Iaccarino, L., Burnham, S. C., Tunali, I., Wang, J., Navitsky, M. A., Arora, A., & Pontecorvo, M. J. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103765 · Cited by 68
AI-driven fusion of multimodal data for Alzheimer’s disease biomarker assessment
Jasodanand, V. H., Kowshik, S. S., Puducheri, S., Romano, M. F., Xu, L., Au, R., & Kolachalama, V. B. (2025) · Nature Communications · doi:10.1038/s41467-025-62590-4 · Cited by 76
Once upon a time, the Amyloid Cascade Hypothesis
Granzotto, A., & Sensi, S. L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102161 · Cited by 57
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“Clinical trials have investigated many anti-A β antibodies, such as solanezumab [145,146], bapineuzumab [147–149], and aducanuamb.”
BackgroundInsights into the use of biomarkers in clinical trials in Alzheimer's disease
Pascoal, T. A., Aguzzoli, C. S., Lussier, F. Z., Crivelli, L., Suemoto, C. K., Fortea, J., Rosa‐Neto, P., Zimmer, E. R., Ferreira, P. C. L., & Bellaver, B. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105322 · Cited by 60
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions
Rafii, M. S., & Aisen, P. S. S. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01123-5 · Cited by 62
Self-citationYang, H., Teng, L., Kang, D., Menon, V., Ge, T., Finucane, H. K., Schultz, A. P., Properzi, M. J., Klein, H., Chibnik, L. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43132-2 · Cited by 56
Self-citationThe advent of Alzheimer treatments will change the trajectory of human aging
Selkoe, D. J. (2024) · Nature Aging · doi:10.1038/s43587-024-00611-5 · Cited by 49
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, M. W., Kanoria, S., Miller, M. J., Aisen, P. S. S., Beckett, L. A., Conti, C., Diaz, A., Flenniken, D., Green, R. C., Harvey, D. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14321 · Cited by 54
Self-citationThe impact of physical exercise on neuroinflammation mechanism in Alzheimer’s disease
Hu, J., Huang, B., & Chen, K. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1444716 · Cited by 55
Chen, Y., Jin, H., Chen, J., Li, J., Găman, M., & Zou, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02600-y · Cited by 56
Jiang, G., Xie, G., Li, X., & Xiong, J. (2025) · Biomolecules · doi:10.3390/biom15060831 · Cited by 48
Walsh, S., Merrick, R. L., Milne, R., Nurock, S., Richard, E., & Brayne, C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14108 · Cited by 44
Rissman, R. A., Donohue, M., Langford, O., Raman, R., Abdel‐Latif, S., Yaari, R., Holdridge, K. C., Sims, J. R., Molina‐Henry, D. P., Jimenez‐Maggiora, G. A., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.134 · Cited by 46
Self-citationConcordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 42
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3
Yaari, R., Holdridge, K. C., Williamson, M., Wessels, A. M., Shcherbinin, S., Kotari, V., Reiman, E. M., Tariot, P. N., Alexander, R., Langbaum, J. B. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70662 · Cited by 45
Self-citationBollack, A., Collij, L. E., García, D. V., Shekari, M., Altomare, D., Payoux, P., Dubois, B., Grau‐Rivera, O., Boada, M., Marquié, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13761 · Cited by 43
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 43
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 40
Wagemann, O., Liu, H., Wang, G., Shi, X., Bittner, T., Scelsi, M. A., Farlow, M. R., Clifford, D. B., Supnet, C. B., Santacruz, A. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.0991 · Cited by 40
Self-citationPassive immunotherapy for Alzheimer’s disease: challenges & future directions
Yi, L., Tan, E. K., & Zhou, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05248-x · Cited by 41
Alzheimer disease seen through the lens of sex and gender
Castro‐Aldrete, L., Einsiedler, M., Martínková, J., Depypere, H. T., Ang, T. F. A., Mielke, M. M., Sindi, S., Eyre, H. A., Au, R., Dimech, A. S., et al. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01071-0 · Cited by 46
De Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 45
Jeong, S. Y., Suh, C. H., Lim, J.-S., Shim, W. H., Heo, H., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J.-H. (2025) · Neurology · doi:10.1212/wnl.0000000000213483 · Cited by 36
Arnsten, A. F. T., Tredici, K. D., Barthélemy, N. R., Gabitto, M. I., van Dyck, C. H., Lein, E. S., Braak, H., & Datta, D. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70404 · Cited by 39
Nonino, F., Minozzi, S., Sambati, L., Del Giovane, C., Baldin, E., Bassi, M. C., De Santis, C., Gonzalez-Lorenzo, M., Vignatelli, L., Filippini, G., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016297 · Cited by 35
Paolis, M. L. D., Paoletti, I., Zaccone, C., Capone, F., D’Amelio, M., & Krashia, P. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00423-y · Cited by 44
MRI-based multi-organ clocks for healthy aging and disease assessment
Cao, H., Song, Z., Duggan, M. R., Erus, G., Srinivasan, D., Tian, Y., Bai, W., Rafii, M. S., Aisen, P. S. S., Belsky, D. W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03999-8 · Cited by 36
Self-citationAisen, P. S. S., Bateman, R. J., Crowther, D. C., Cummings, J., Dwyer, J. R., Iwatsubo, T., Kosco‐Vilbois, M. H., McDade, E., Mohs, R. C., Scheltens, P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14342 · Cited by 34
Self-citationThe Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 32
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
Baumeister, H., Vogel, J. W., Insel, P. S., Kleineidam, L., Wolfsgruber, S., Stark, M., Gellersen, H. M., Yakupov, R., Schmid, M. C., Lüsebrink, F., et al. (2024) · Brain · doi:10.1093/brain/awae118 · Cited by 33
Bellelli, F., Angioni, D., Arosio, B., Vellas, B. J., & Barreto, P. D. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102699 · Cited by 34
Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
Zhang, Y., Chen, J., Li, Y., Jiao, B., & Luo, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102595 · Cited by 34
Stern, R. A., Trujillo‐Rodriguez, D., Tripodis, Y., Pulukuri, S. V., Alosco, M. L., Adler, C. H., Balcer, L. J., Bernick, C. B., Baucom, Z., MAREK, K. L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01315-5 · Cited by 31
Self-citationInsel, P. S., Mattsson, N., Langford, O., Caruso, V. M., Leuzy, A., Young, C. B., Boxer, A. L., Aisen, P. S. S., Sperling, R. A., Mormino, E. C., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2974 · Cited by 35
Self-citationDubbelman, M. A., Hendriksen, H. M. A., Harrison, J., Vijverberg, E. G. B., Prins, N. D., Kroeze, L. A., Ottenhoff, L., van Leeuwenstijn, M. S. S. A., Verberk, I. M. W., Teunissen, C. E., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207978 · Cited by 27
Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2024) · Brain · doi:10.1093/brain/awae216 · Cited by 36
Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy
Almohmadi, N. H., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Abdelaziz, A. M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103639 · Cited by 29
Panza, F., Dibello, V., Sardone, R., Zupo, R., Castellana, F., Leccisotti, I., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2463963 · Cited by 28
Recent advances in neuroimaging of Alzheimer's disease and related dementias
Ottoy, J., Owsicki, N., Bilgel, M., Binette, A. P., Salvadó, G., Kang, M. S., Cash, D. M., Ewers, M., Joie, R. L., Wisse, L. E. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70648 · Cited by 30
Causal cardiovascular risk factors for dementia: insights from observational and genetic studies
Kjeldsen, E. W., & Frikke‐Schmidt, R. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae235 · Cited by 29
Blood-derived factors to brain communication in brain diseases
He, J., Zhang, Y., Guo, Y., Guo, J., Chen, X., Xu, S., Xu, X., Wu, C., Liu, C., Chen, J., et al. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.09.022 · Cited by 26
Dumitrascu, O. M., Doustar, J., Fuchs, D.-T. S., Koronyo, Y., Sherman, D. S., Miller, M. S., Johnson, K., Carare, R. O., Verdooner, S. R., Lyden, P. D., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01810-2 · Cited by 25
Self-citationImmunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy
Mahboob, A., Ali, H., Naimi, A. J. A., Yousef, M., Rob, M., Al-Muhannadi, N. A., Senevirathne, D. K. L., & Châari, A. (2024) · Cells · doi:10.3390/cells13181527 · Cited by 26
Tian, L., Long, G., Zhu, S., Wang, Y., Xu, P., Liu, L., Yao, H., Fang, S., Chen, S., & Li, S. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2427257122 · Cited by 27
Vaghari, D., Mohankumar, G., Tan, K., Lowe, A., Shering, C., Peter Tiňo, B., & Kourtzi, Z. (2025) · Nature Communications · doi:10.1038/s41467-025-61355-3 · Cited by 24
Wang, G., Cutter, G., Oxtoby, N. P., Shan, G., Wang, W., Mangal, B., Liao, Y., Llibre‐Guerra, J. J., Li, Y., Xiong, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14035 · Cited by 23
Vukmir, R. B. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52042 · Cited by 24
New and emerging drug therapies for Alzheimer disease
Waite, L. M. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.021 · Cited by 22
Molecular Therapeutics in Development to Treat Alzheimer’s Disease
Tartaglia, M. C., & Ingelsson, M. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00738-6 · Cited by 23
Marković, M., Milošević, J. R., Wang, W., & Cao, Y. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000726 · Cited by 20
Lian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 25
Self-citationImmunotherapy: An emerging treatment option for neurodegenerative diseases
Mukherjee, A., Biswas, S., & Roy, I. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103974 · Cited by 22
Molina‐Henry, D. P., Langford, O., Donohue, M., Raman, R., Aisen, P. S. S., Johnson, K. A., Rissman, R. A., & Sperling, R. A. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.124 · Cited by 20
Self-citationImmune Modulation in Alzheimer’s Disease: From Pathogenesis to Immunotherapy
Balkhi, S., Spirito, A. D., Poggi, A. D., & Mortara, L. (2025) · Cells · doi:10.3390/cells14040264 · Cited by 21
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19
Zeng, B., Tang, C., Wang, J., Yang, Q., Ren, Q., & Liu, X. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240161 · Cited by 20
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 24
Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline
Trieu, C., van Harten, A. C., van Leeuwenstijn, M. S. S. A., Schlüter, L., Boonkamp, L., Aladdin, A., Sikkes, S. A. M., van de Giessen, E., Verberk, I. M. W., Teunissen, C. E., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.45862 · Cited by 18
Sheikh, M., & Ammar, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1398952 · Cited by 23
Boyle, R. T., Klinger, H. M., Shirzadi, Z., Coughlan, G., Seto, M., Properzi, M. J., Townsend, D. L., Yuan, Z., Scanlon, C. E., Jutten, R. J., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.140 · Cited by 17
Self-citation[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer’s disease
Li, A., Zhao, R., Zhang, M., Sun, P., Cai, Y. Q., Zhu, L., Kung, H. F., Han, Y., Wang, X., & Guo, T. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06835-2 · Cited by 17
REAL AD—Validation of a realistic screening approach for early Alzheimer's disease
Leuzy, A., Heeman, F., Bosch, I., Lenér, F., Dottori, M. G., Quitz, K., Moscoso, A., Kern, S., Zetterberg, H., Blennow, K., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14219 · Cited by 15
Wang, Q., Chen, S., Wang, J., Shang, H., & Chen, X. (2024) · Brain Sciences · doi:10.3390/brainsci14100990 · Cited by 18
Longitudinal Trajectories of the Cognitive Function Index in the A4 Study
Amariglio, R. E., Grill, J. D., Rentz, D. M., Marshall, G. A., Donohue, M., Liu, A., Aisen, P. S. S., & Sperling, R. A. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.125 · Cited by 16
Self-citationEvaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials
Ferreira, P. C. L., Bellaver, B., Povala, G., Bauer‐Negrini, G., Aguzzoli, C. S., Ferrari‐Souza, J. P., Leffa, D. T., Soares, C., Lussier, F. Z., Medeiros, M. S., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000214441 · Cited by 18
Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 17
Development of disease‐modifying therapies against Alzheimer's disease
Iwatsubo, T. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13681 · Cited by 20
Self-citationBlood tests could soon predict your risk of Alzheimer’s
Abbott, A. (2024) · Nature · doi:10.1038/d41586-024-02535-x · Cited by 15
Gehlot, P., Pathak, R., Kumar, S., Choudhary, N. K., & Vyas, V. K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117925 · Cited by 18
Vanderlip, C. R., & Stark, C. E. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70355 · Cited by 15
Towards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 18
Yang, H. Y., Anzai, J. A. U., Yau, W. W., Healy, B. C., Viera, A. M. R., Maa, C., Kirn, D. R., Properzi, M. J., Bellier, J., Schultz, A. P., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71269-3 · Cited by 16
Self-citationSerrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 20
Self-citationPET imaging of TREM2 in amyloid-beta induced neuroinflammation
Dahlén, A. D., Roshanbin, S., Aguilar, X., Bucher, N. M., van den Broek, S. L., Sehlin, D., & Syvänen, S. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07358-0 · Cited by 15
Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 16
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
Elamin, S. A., Shibli, A. N. A., Shaito, A. A., Al-Maadhadi, M., Zolezzi, M., & Pedersen, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.011 · Cited by 15
Beyond Macrostructure: Is There a Role for Radiomics Analysis in Neuroimaging ?
Das, S. R., Ilesanmi, A. E., Wolk, D. A., & Gee, J. C. (2024) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.rev.2024-0053 · Cited by 18
Amyloid-PET imaging predicts functional decline in clinically normal individuals
Quenon, L., Collij, L. E., García, D. V., Alves, I. L., Gérard, T., Malotaux, V., Huyghe, L., Gispert, J. D., Jessen, F., Visser, P. J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01494-9 · Cited by 15
Alzheimer’s disease and immunotherapy
Qin, W., Pang, Y., Nie, S., Quan, M., & Jia, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00035-8 · Cited by 15
Metadata
- Authors
- Sperling, R. A., Donohue, M. C., Raman, R., Rafii, M. S., Johnson, K., Masters, C. L., van Dyck, C. H., Iwatsubo, T., Marshall, G. A., Yaari, R., Mancini, M., Holdridge, K. C., Case, M., Sims, J. R., & Aisen, P. S.
- Affiliations
- University of Southern California (US)
- From the Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School (R.A.S., G.A.M.), and the Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School (K.J.) — both in Boston; Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego (M.C.D., R.R., M.S.R., P.S.A.); the Florey Institute, University of Melbourne, Melbourne, VIC, Australia (C.L.M.); the Departments of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, New Haven, CT (C.H.D.); the Department of Neuropathology, Graduate School of Medicine, University of Tokyo, Tokyo (T.I.); and Eli Lilly, Indianapolis (R.Y., M.M., K.C.H., M.C., J.R.S.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1096-1107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10559996
- OpenAlex
- W4384523451
- Cited by
- 429
- References
- 36
- Citations by year
- 2026: 140 · 2025: 153 · 2024: 115 · 2023: 21
- FWCI
- 76.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer’s Association
- Accelerating Medicines Partnership through the Foundation for the National Institutes of Health
- GHR Foundation
- Davis Alzheimer Prevention Program
- anonymous foundation
- National Institute on Aging (R01AG063689, U19AG010483, U24AG057437)
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- solanezumab, preclinical Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive decline, amyloid PET, 18F-florbetapir, amyloid-related imaging abnormalities, aria, Alzheimer's disease prevention, brain amyloid burden
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Amyloid beta-Peptides, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
